LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

MiNK Therapeutics

Uždarymo kaina

11

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.56

Max

11

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.4M

-2.9M

Pelnas, tenkantis vienai akcijai

-0.65

Darbuotojai

23

EBITDA

1.3M

-2.8M

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-10M

52M

Ankstesnė atidarymo kaina

11

Ankstesnė uždarymo kaina

11

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

MiNK Therapeutics Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-18 22:31; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026-02-18 22:18; UTC

Uždarbis

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026-02-18 22:11; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026-02-18 21:52; UTC

Uždarbis

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026-02-18 23:56; UTC

Rinkos pokalbiai

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026-02-18 23:34; UTC

Rinkos pokalbiai
Uždarbis

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026-02-18 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026-02-18 23:32; UTC

Rinkos pokalbiai

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026-02-18 22:45; UTC

Uždarbis

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026-02-18 22:44; UTC

Rinkos pokalbiai

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q EPS $1.18 >NTR.T

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q Sales $5.34B >NTR.T

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q EPS $1.07 >PAAS

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q Rev $1.18B >PAAS

2026-02-18 22:30; UTC

Uždarbis

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026-02-18 22:29; UTC

Uždarbis

Kinross Gold 4Q EPS 75c >K.T

2026-02-18 22:22; UTC

Uždarbis

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026-02-18 22:22; UTC

Rinkos pokalbiai

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026-02-18 22:16; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026-02-18 22:05; UTC

Uždarbis

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026-02-18 22:03; UTC

Uždarbis

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Sales $929M >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Adj EPS 67c >KGC

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Sales $2.02B >KGC

2026-02-18 21:56; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026-02-18 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

MiNK Therapeutics Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

0

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

7.81 / 8.1Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

help-icon Live chat